Effect of a thromboxane synthetase inhibitor, ozagrel hydrochloride, on peak expiratory flow in stable asthmatics treated with beclomethasone diproprionate

Effect of a thromboxane synthetase inhibitor, ozagrel hydrochloride, on peak expiratory flow in stable asthmatics treated with beclomethasone diproprionate

Steroid inhalation therapy is recommended for treatment of moderate to severe asthma, but it is unknown whether the therapy sufficiently suppresses production of thromboxane A2 (TXA2), one of the inflammatory lipid mediators. The effect of a selective orally active thromboxane synthesis inhibitor, o...

Full description

Bibliographic Details
Main Authors: Masaki Fujimura, Yasuto Nakatsumi, Kouichi Nishi, Haruhiko Ogawa, Kazuo Kasahara, Tamotsu Matsuda
Format: Article
Language:English
Published: Elsevier 1997-01-01
Series:Allergology International
Subjects:
asthma
ozagrel hydrochloride
peak expiratory flow
steroid inhalation therapy
thromboxane synthetase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893015315768

Similar Items

Similar Items